Prognostic impact of germline BRCA1/2 pathogenic variants in breast cancer-Reference-Cited by-同舟云学术

Prognostic impact of germline BRCA1/2 pathogenic variants in breast cancer

Published:2022-11-04 Issue:1 Volume:197 Page:103-112
ISSN:0167-6806
Container-title:Breast Cancer Research and Treatment
language:en
Short-container-title:Breast Cancer Res Treat

Author:

Corso Giovanni^ORCID,Girardi Antonia,Calvello Mariarosaria,Gandini Sara,Gaeta Aurora,Marabelli Monica,Magnoni Francesca,Veronesi Paolo,Guerrieri-Gonzaga Aliana,Bonanni Bernardo

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

https://link.springer.com/content/pdf/10.1007/s10549-022-06776-0.pdf

Reference26 articles.

1. Tung N, Desai N (2021) Germline genetic testing for women with breast cancer: shifting the paradigm from whom to test to whom not to test. J Clin Oncol 39(31):3415–3418. https://doi.org/10.1200/JCO.21.01761

2. Gonzalez-Angulo AM, Timms KM, Liu S, Chen H, Litton JK, Potter J, Lanchbury JS, Stemke-Hale K, Hennessy BT, Arun BK, Hortobagyi GN, Do KA, Mills GB, Meric-Bernstam F (2011) Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer. Clin Cancer Res 17(5):1082–1089. https://doi.org/10.1158/1078-0432.CCR-10-2560

3. King MC, Marks JH, Mandell JB, New York Breast Cancer Study Group (2003) Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 302(5645):643–646. https://doi.org/10.1126/science.1088759

4. Kuchenbaecker KB, Hopper JL, Barnes DR, Phillips KA, Mooij TM, Roos-Blom MJ, Jervis S, van Leeuwen FE, Milne RL, Andrieu N, Goldgar DE, Terry MB, Rookus MA, Easton DF, Antoniou AC, BRCA1 and BRCA2 Cohort Consortium, McGuffog L, Evans DG, Barrowdale D, Frost D, Adlard J, Ong KR, Izatt L, Tischkowitz M, Eeles R, Davidson R, Hodgson S, Ellis S, Nogues C, Lasset C, Stoppa-Lyonnet D, Fricker JP, Faivre L, Berthet P, Hooning MJ, van der Kolk LE, Kets CM, Adank MA, John EM, Chung WK, Andrulis IL, Southey M, Daly MB, Buys SS, Osorio A, Engel C, Kast K, Schmutzler RK, Caldes T, Jakubowska A, Simard J, Friedlander ML, McLachlan SA, Machackova E, Foretova L, Tan YY, Singer CF, Olah E, Gerdes AM, Arver B, Olsson H (2017) Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA 317:2402–2416

5. Rauh C, Gass P, Heusinger K, Haeberle L, Jud SM, Hein A, Loehberg CR, Lux MP, Wachter DL, Heimrich J, Strehl JD, Haller F, Hartmann A, Schulz-Wendtland R, Fiessler C, Beckmann MW, Fasching PA, Poehls U (2015) Association of molecular subtypes with breast cancer risk factors: a case-only analysis. Eur J Cancer Prev 24(6):484–490. https://doi.org/10.1097/CEJ.0000000000000111

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Harnessing Epigenetics for Breast Cancer Therapy: The Role of DNA Methylation, Histone Modifications, and MicroRNA;International Journal of Molecular Sciences;2023-04-13